Europe Diabetic Foot Ulcer Treatment Market to Grow with a CAGR of 5.70% through 2028

Multidisciplinary approaches to care, patient education, regulatory support, and digital health solutions are expected to drive the Europe Diabetic Foot Ulcer Treatment Market growth in the forecast period, 2024-2028.

According to TechSci Research report, “Europe Diabetic Foot Ulcer Treatment Market –Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Europe Diabetic Foot Ulcer Treatment Market stood at USD 1.53 billion in 2022 and is anticipated to grow with a CAGR of 5.70% in the forecast period, 2024-2028. This can be attributed to patient awareness and education. Increasing efforts to raise awareness about the risks of DFUs and the importance of preventive measures have contributed to early intervention. Patients are now more informed about diabetes management and foot care, resulting in reduced incidence rates. However, this has also led to a heightened demand for DFU treatment solutions, further driving market growth.

Moreover, the healthcare industry is becoming more environmentally conscious, and this trend is extending to wound care products. There is a growing demand for sustainable and eco-friendly wound care materials and packaging, reflecting the broader global shift toward sustainability.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Europe Diabetic Foot Ulcer Treatment Market”

Diabetes stands as one of the most prevalent health conditions among elderly individuals in Europe. In 2019, it affected approximately 19.3 million people aged 60-79, 11.3 million in the 40-59 age group, and 1.7 million aged 20-39. Among the European nations, Germany had the highest diabetic population share, accounting for approximately 10.5%, followed by Portugal at around 9.5%, and Cyprus with about 9.0%. While the prevalence of diabetes has stabilized in many parts of the region, it is on the rise in Southern European countries and Central & Eastern European countries. Factors such as increasing obesity and sedentary lifestyles are believed to contribute to this upward trend in diabetes. Poorly managed diabetes can lead to severe complications, including blindness, kidney failure, heart attacks, liver problems, and limb amputations due to untreated foot ulcers. Globally, the prevalence of foot ulcers in diabetic patients ranges from 4.0% to 10.0%, with an incidence rate between 1.0% and 4.1%. According to statistics from the International Diabetes Federation, approximately 10% to 15% of diabetic patients may develop foot ulcers at least once in their lifetime, with Type 2 diabetics being at a higher risk compared to Type 1 diabetics.

Diabetic foot ulcers (DFUs) are a leading cause of hospitalization among individuals with diabetes, with a significant number of cases resulting in lower limb amputations. The prevalence of DFUs varies significantly across continents. In 2016, North America reported the highest prevalence of DFUs at 13.0%, followed by Africa (7.2%), Asia (5.5%), and Europe (5.1%). The COVID-19 pandemic has further exacerbated the prevalence of diabetes and its fatal complications. Clinicians faced significant challenges in managing diabetic foot ulcers during the pandemic due to limited access to laboratories, radiological testing, and reduced admissions in healthcare facilities.

Despite the adoption of telehealth and telemedicine, diabetic foot ulcers still required personalized attention and care. This resulted in a surge in demand for DFU management tools in the market, prompting manufacturers to increase their supply. Companies like Smith and Nephew reported increased revenues in 2020, driven by strong sales of their leading DFU care products. Additionally, studies published by the British Diabetic Association revealed that in England, nearly 5% of COVID-19-infected patients developed diabetes within seven months after discharge. As a result, the need for DFU treatment products increased in large and small-scale hospitals, community clinics, surgery centers, nursing homes, and outpatient care settings.

The Europe Diabetic Foot Ulcer Treatment Market is segmented into treatment, ulcer type, regional distribution, and company.

Based on its treatment, the biologics segment held the dominant position in the regional market in 2022 and contributed the most significant portion of the total revenue. It is anticipated that this segment will continue to experience rapid growth with the highest Compound Annual Growth Rate (CAGR) throughout the forecast period. Biologics encompasses a range of treatments including growth factors like Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF), stem cells, and other medications for diabetes management. These substances play a crucial role in reducing high blood sugar levels, improving oxygenation and blood circulation, as well as facilitating tissue regeneration. Consequently, they are increasingly being utilized for managing wounds at various stages, making them an ideal choice for treating Diabetic Foot Ulcers (DFUs).

In 2022, wound care dressings held the second-largest share of the global revenue, following therapy devices and antibiotic medications. Within the wound care category, there are various types of dressings, including alginate dressings, hydro fiber dressings, foam dressings, film dressings, hydrocolloid dressings, surgical dressings, and hydrogel dressings. Foam dressings emerged as the leading choice in 2022 due to their ability to absorb wound exudate while maintaining an optimal level of moisture on the wound surface. Typically, polyurethane foam dressings are directly applied or layered with an antimicrobial coating on the affected area and then secured with gauze or a bandage to provide compression.

Based on region, Germany took the lead in the industry in 2022 and contributed the largest portion of the total revenue. This growth can be attributed to the country having the highest diabetic patient population. Globally, an estimated 463 million adults have diabetes, with Europe alone accounting for 59 million of these cases. In 2019, the prevalence rate of diabetes had risen to 15.3%, up from 12.2% in 2017. This translates to approximately 9.5 million people living with diabetes in Germany, of which 4.5 million cases remain undiagnosed. About 6% of pregnant women in Germany experience gestational diabetes each year. The increasing incidence of diabetes in the country has consequently led to a significant increase in the demand for diabetic foot ulcer treatment, driving industry growth.

Other countries in the region, including the U.K., Italy, Spain, and France, also play a significant role. According to the International Diabetes Federation, there were 747,600 cases of diabetes in Germany and 3.8 million individuals with diabetes in the U.K. Approximately 10% of these diabetes patients develop foot ulcers during their lifetime. Germany reports more than 7,000 cases of diabetes-related amputations annually. In the U.K., 8.8% of diabetes-related hospital admissions are linked to amputations and ulcers. Approximately 25% of people with diabetes experience foot ulceration at some point in their lives. Each year, over 22,000 individuals with diabetes mellitus undergo leg amputations as a result.

Major companies operating in Europe Diabetic Foot Ulcer Treatment Market are:

• ConvaTec Inc
• Acelity LP Inc
• 3M Health Care
• Coloplast Corp
• Smith & Nephew PLC
• B Braun Melsungen AG 
• Medline Industries Inc
• Organogenesis Inc
• Molnlycke Health Care AB
• Medtronic PLC

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The Europe Diabetic Foot Ulcer Treatment Market is witnessing a wave of innovation and transformation. As technology and research continue to advance, the treatment options and strategies available for DFUs are becoming more sophisticated, personalized, and patient-centered. The emerging trends hold promise for better patient outcomes, reduced healthcare costs, and an overall improved quality of life for individuals living with DFUs in Europe. Stakeholders in the healthcare sector must stay abreast of these trends to provide the best care and leverage opportunities for growth and innovation in the market,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

“Europe Diabetic Foot Ulcer Treatment Market By Treatment (Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications, Others), By Ulcer Type (Neuropathic Ulcers, Ischemic Ulcers, Neuro-ischemic Ulcers), By Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated the future growth potential of Europe Diabetic Foot Ulcer Treatment Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Europe Diabetic Foot Ulcer Treatment Market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: www.techsciresearch.com